We directed our research towards the study of the A2AR in gliomas, it is an inhibitory checkpoint of the immune system, which by blocking it with an antagonist has shown efficacy in other types of cancer, by improving the anti-tumor immune response [14,15,16,17,18]. This evidence concerns the gene ADORA2A and central nervous system cancer.